Science & Technology
Tue, March 20, 2012 
OMAHA, Neb.--([ BUSINESS WIRE ])--Transgenomic, Inc. (OTCBB: TBIO) today announced that Craig Tuttle, Chief Executive Officer of Transgenomic, will be presenting at the 2012 Maxim Group Growth Conference on Monday, March 26, 2012 at 3:00 PM Eastern Time in New York City.
The presentation will be webcast live at [ http://wsw.com/webcast/max4/tbio/ ]and is available for viewing at the Companyas web site at [ http://www.transgenomic.com/events.asp?id=6 ], where it will be archived for 90 days.
About Transgenomic
Transgenomic, Inc. ([ www.transgenomic.com ]) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.
